(IN BRIEF) The FDA has awarded orphan drug designation to Sanofi’s riliprubart for the treatment of antibody-mediated rejection in solid organ transplants, highlighting the therapy’s potential in an area lacking approved options. Riliprubart, a humanized IgG4 antibody targeting activated C1s … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Security & Safety, Technology
Tagged Alyssa Johnsen, AMR, antibody-mediated rejection, C1s inhibition, chronic inflammatory demyelinating polyneuropathy, CIDP, ClinicalTrials.gov, complement pathway, FDA, Global Therapeutic Area Development Head, immunology, MOBILIZE, NCT05156710, NCT06290128, NCT06290141, orphan drug designation, Phase 2 study, riliprubart, Sanofi, SAR445088, solid organ transplantation, VITALIZE
Novartis announces that researchers can now request access to patient level data on newly approved innovative medicines in the United States and EU in 2014 through the Idea Point portal, and is committed to enhancing Clinical Study Report summaries for … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, Science, Switzerland
Tagged Clinical Study Reports, clinical trial data transparency, ClinicalTrials.gov, data transparency, innovative medicines, Novartis, Tim Wright, voluntarily disclosing summaries, voluntarily disclosing summaries of Clinical Study Reports
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?